Author: Editor

Neeraj Agarwal, MD, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI. In this video, he speaks about Prostate Cancer OS Is Up Significantly.   Observation –   Intention:   Orteronel (TAK-700) is a nonsteroidal androgen-suppressing 17,20-lyase inhibitor. We looked at how orteronel performed when combined with androgen deprivation therapy (ADT) in individuals with newly diagnosed metastatic hormone-sensitive prostate cancer.   Methodology:   Patients with metastatic hormone-sensitive prostate cancer were randomly…

EXUMA Biotech’s VP of Oncology R&D, Dr. Sid Kerkar, Reveals Preclinical Data From Its Subcutaneous CAR-TaNK And In Vivo CAR Cell And Gene Therapy Programs  EXUMA Biotech, Corp., is a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors.  EXUMA is currently conducting IND-enabling studies of the first products on its CAR-TaNK cell therapy platform, targeting CD19 and CD22. CAR-TaNKs are potent cancer killers with T and NK features, which preclinically have been observed to reproducibly and robustly expand in vivo in lymphoreplete animal models following the generation of synthetic lymph nodes post subcutaneous injection. Based…

Maria Soledad Sosa, Ph.D.,  Assistant Professor of Pharmacological Sciences, and Oncological Sciences, at The Tisch Cancer Institute at Mount Sinai. In this video, she speaks about the Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients.   Mount Sinai researchers have found a previously unknown process by which non-malignant cells from early breast cancer tumors migrate to other organs before “turning on” and becoming metastatic breast cancer.   The researchers also demonstrated the ability of the transcription factor NR2F1, a protein that controls a gene’s outward expression, to prevent pre-malignant cells from spreading,…

Maria Soledad Sosa, Ph.D.,  Assistant Professor of Pharmacological Sciences, and Oncological Sciences, at The Tisch Cancer Institute at Mount Sinai. In this video, she speaks about the Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients.   Mount Sinai researchers have found a previously unknown process by which non-malignant cells from early breast cancer tumors migrate to other organs before “turning on” and becoming metastatic breast cancer.   The researchers also demonstrated the ability of the transcription factor NR2F1, a protein that controls a gene’s outward expression, to prevent pre-malignant cells from spreading,…

Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center. In this video, he speaks about the New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients.   Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with advanced or metastatic breast cancer that is hormone receptor-positive but not human epidermal growth factor receptor-2 negative (HR+/HER2-). The examination of patients treated in first-line with Kisqali + fulvestrant revealed an…

Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center. In this video, he speaks about the New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients.   Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with advanced or metastatic breast cancer that is hormone receptor-positive but not human epidermal growth factor receptor-2 negative (HR+/HER2-). The examination of patients treated in first-line with Kisqali + fulvestrant revealed an…

Roy S. Herbst, MD, Ph.D., Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer.   Summary:   COAST is a Phase 2 open-label, multicenter, randomized multidrug platform research comparing the effectiveness and safety of durvalumab alone with durvalumab in combination with…

Roy S. Herbst, MD, Ph.D., Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer.   Summary:   COAST is a Phase 2 open-label, multicenter, randomized multidrug platform research comparing the effectiveness and safety of durvalumab alone with durvalumab in combination with…

James Yarmolinsky, Ph.D., Research Fellow at the University of Bristol. In this video, he speaks about Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.   Observation –   Origins:   In high-income countries, endometrial cancer is the most frequent gynaecological malignancy. Elevated BMI is a known modifiable risk factor for this condition, and it is thought to have a greater impact on endometrial cancer risk than any other cancer site. The molecular processes behind this relationship, however, remain unknown. Mendelian randomization (MR) was utilized to investigate the involvement of 14…

James Yarmolinsky, Ph.D., Research Fellow at the University of Bristol. In this video, he speaks about Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.   Observation –   Origins:   In high-income countries, endometrial cancer is the most frequent gynaecological malignancy. Elevated BMI is a known modifiable risk factor for this condition, and it is thought to have a greater impact on endometrial cancer risk than any other cancer site. The molecular processes behind this relationship, however, remain unknown. Mendelian randomization (MR) was utilized to investigate the involvement of 14…

Raja M. Flores, MD, Professor and System Chair, Thoracic Surgery at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the Menthol Cigarette Ban.The US Food and Drug Administration announced today proposed product guidelines that would restrict menthol as a defining taste in cigarettes and all characterizing flavors (other than tobacco) in cigars. By reducing juvenile experimentation and addiction and increasing the number of smokers who quit, these initiatives have the potential to considerably reduce disease and death from combusted tobacco product use, the main cause of preventable death in the United States.These proposed product standards…

Raja M. Flores, MD, Professor and System Chair, Thoracic Surgery at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the Menthol Cigarette Ban.The US Food and Drug Administration announced today proposed product guidelines that would restrict menthol as a defining taste in cigarettes and all characterizing flavors (other than tobacco) in cigars. By reducing juvenile experimentation and addiction and increasing the number of smokers who quit, these initiatives have the potential to considerably reduce disease and death from combusted tobacco product use, the main cause of preventable death in the United States.These proposed product standards…

Cansu Cimen Bozkus, PhD, Assistant Professor at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 abstract – 253 / 19 – Analyses of tumor-specific T cell dynamics and tumor immune contexture in microsatellite instability-high cancers in response to first-line therapy.Overview:The MSI-H phenotype is caused by faulty DNA repair processes and is present in many cancers, including colorectal and endometrial cancers. MSI-H malignancies can be used to research the aspects of neoantigen-induced anti-tumor immunity in response to therapy and disease outcome due to large neoantigen loads produced from tumor-specific mutations, evidence of tumor-infiltrating…

Cansu Cimen Bozkus, PhD, Assistant Professor at Icahn School of Medicine at Mount Sinai. In this video, she speaks about the AACR 2022 abstract – 253 / 19 – Analyses of tumor-specific T cell dynamics and tumor immune contexture in microsatellite instability-high cancers in response to first-line therapy.Overview:The MSI-H phenotype is caused by faulty DNA repair processes and is present in many cancers, including colorectal and endometrial cancers. MSI-H malignancies can be used to research the aspects of neoantigen-induced anti-tumor immunity in response to therapy and disease outcome due to large neoantigen loads produced from tumor-specific mutations, evidence of tumor-infiltrating…

Zeina Nahleh, MD, FACP, Cancer Center Director and Department Chair, Hematology-Oncology at the Cleveland Clinic. In this video, she speaks about The Use of Biosimilars in Oncology.   Outline   PURPOSE:    The rising quantity and use of biosimilars raises fundamental questions about their safe and acceptable use in cancer therapy. This paper gives an update on recently licensed oncology biosimilars as well as outlines existing knowledge gaps in cancer patient treatment.   Methodology:   An Expert Panel was formed to assess the medical literature and provide a practical summary of currently approved biosimilar therapies in the United States for…

Zeina Nahleh, MD, FACP, Cancer Center Director and Department Chair, Hematology-Oncology at the Cleveland Clinic. In this video, she speaks about The Use of Biosimilars in Oncology.   Outline   PURPOSE:   The rising quantity and use of biosimilars raises fundamental questions about their safe and acceptable use in cancer therapy. This paper gives an update on recently licensed oncology biosimilars as well as outlines existing knowledge gaps in cancer patient treatment.   Methodology:   An Expert Panel was formed to assess the medical literature and provide a practical summary of currently approved biosimilar therapies in the United States for…

Nichole James, Ph.D., Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women and Infants Hospital. In this video, she speaks about the abstract Prognostic immunologic signatures in epithelial ovarian cancer.   Abstract:   Epithelial Ovarian Cancer (EOC) is a lethal gynecologic cancer that usually recurs after initial platinum-taxane chemotherapy. EOC clinical studies, like those for many other cancer subtypes, have focused on immunotherapeutic methods, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies have been modest in EOC patients, data suggests that ovarian cancers are immunogenic and that immune-related genetic profiles can…

Nichole James, Ph.D., Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women and Infants Hospital. In this video, she speaks about the abstract Prognostic immunologic signatures in epithelial ovarian cancer.   Abstract:   Epithelial Ovarian Cancer (EOC) is a lethal gynecologic cancer that usually recurs after initial platinum-taxane chemotherapy. EOC clinical studies, like those for many other cancer subtypes, have focused on immunotherapeutic methods, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies have been modest in EOC patients, data suggests that ovarian cancers are immunogenic and that immune-related genetic profiles can…

Lajos Pusztai, MD, DPhil, Professor of Medicine, Co-Leader Genetics, Genomics, and Epigenetics Program, Scientific Co-Director of the Center for Breast Cancer, Yale Cancer Center. In this video, he speaks about the Cancer Relevance of Human Genes.   Observation –   Origins:   We postulate that genes that interact with core cancer genes (CCG) directly or indirectly in a comprehensive gene-gene interaction network may have functional value in cancer.   Methodologies:   We classified 12,767 human genes into CCGs (n = 468), one (n = 5,467), two (n = 5,573), three (n = 915), and more than three (n = 416)…

Lajos Pusztai, MD, DPhil, Professor of Medicine, Co-Leader Genetics, Genomics, and Epigenetics Program, Scientific Co-Director of the Center for Breast Cancer, Yale Cancer Center. In this video, he speaks about the Cancer Relevance of Human Genes.   Observation –   Origins:   We postulate that genes that interact with core cancer genes (CCG) directly or indirectly in a comprehensive gene-gene interaction network may have functional value in cancer.   Methodologies:   We classified 12,767 human genes into CCGs (n = 468), one (n = 5,467), two (n = 5,573), three (n = 915), and more than three (n = 416)…

Sanika Bodas, Ph.D., Ph.D. Student at University of Nebraska Medical Center. In this video, she speaks about the AACR 2022 Abstract – LB035 / 7 – Understanding the mechanism of neuropilin2 upregulation in advanced prostate cancer.   Observation –   Origins:   Androgen Deprivation Therapy (ADT) is used to treat prostate cancer (ADT). Patients with advanced prostate cancer develop resistance to ADT and progress to a fatal phenotype known as Castration Resistant Prostate Cancer (CRPC). Neuropilin-2 expression is increased in advanced prostate cancer. It has been linked to a decrease in overall survival in these individuals by generating therapeutic resistance.…

Sanika Bodas, Ph.D., Ph.D. Student at University of Nebraska Medical Center. In this video, she speaks about the AACR 2022 Abstract – LB035 / 7 – Understanding the mechanism of neuropilin2 upregulation in advanced prostate cancer.   Observation –   Origins:   Androgen Deprivation Therapy (ADT) is used to treat prostate cancer (ADT). Patients with advanced prostate cancer develop resistance to ADT and progress to a fatal phenotype known as Castration Resistant Prostate Cancer (CRPC). Neuropilin-2 expression is increased in advanced prostate cancer. It has been linked to a decrease in overall survival in these individuals by generating therapeutic resistance.…

Claire Rosean, Ph.D., Senior Scientist at Immunomic Therapeutics. In this video, she speaks about the AACR 2022 Abstract – 2052 / 10 – ITI-3000 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses, tumor inhibition, and provides rationale for first-in-human trial.   Overview:   The majority of Merkel cell carcinomas (MCC), a rare and deadly type of neuroendocrine skin cancer, are caused by Merkel cell polyomavirus (MCPyV). MCPyV integrates into the host genome, causing infected cells to express a shortened form of the viral large T antigen (LT), making LT an appealing target…

Claire Rosean, Ph.D., Senior Scientist at Immunomic Therapeutics. In this video, she speaks about the AACR 2022 Abstract – 2052 / 10 – ITI-3000 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses, tumor inhibition, and provides rationale for first-in-human trial.   Overview: The majority of Merkel cell carcinomas (MCC), a rare and deadly type of neuroendocrine skin cancer, are caused by Merkel cell polyomavirus (MCPyV). MCPyV integrates into the host genome, causing infected cells to express a shortened form of the viral large T antigen (LT), making LT an appealing target for…

Linda Kachuri, PhD, Postdoctoral Scholar, Epidemiology & Biostatistics at UC San Francisco. In this video, she speaks about the AACR 2022 Abstract – 1441 / 8 – Genetic determinants of PSA levels improve prostate cancer screening.   Overview:   PSA screening for prostate cancer (PCa) remains contentious due to low sensitivity and specificity, which leads to overdiagnosis and overtreatment. Our study’s goal is to identify genetic drivers of PSA levels in cancer-free men in order to tailor PCa screening. We expect that accounting for PSA variance that is related to genetic factors and does not reflect PCa will enhance test…

Linda Kachuri, PhD, Postdoctoral Scholar, Epidemiology & Biostatistics at UC San Francisco. In this video, she speaks about the AACR 2022 Abstract – 1441 / 8 – Genetic determinants of PSA levels improve prostate cancer screening.   Overview:   PSA screening for prostate cancer (PCa) remains contentious due to low sensitivity and specificity, which leads to overdiagnosis and overtreatment. Our study’s goal is to identify genetic drivers of PSA levels in cancer-free men in order to tailor PCa screening. We expect that accounting for PSA variance that is related to genetic factors and does not reflect PCa will enhance test…

This series offers two interactive programs supported by audio and video commentary, where Dr. Justin Gainor and Dr. Maria Arcila share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:   • Increase implementation of best practices for EGFR mutation testing in patients with NSCLC • Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC • Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC   To learn more and participate in the activities,…

This series offers two interactive programs supported by audio and video commentary, where Dr. Justin Gainor and Dr. Maria Arcila share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:   • Increase implementation of best practices for EGFR mutation testing in patients with NSCLC • Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC • Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC   To learn more and participate in the activities,…

Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, Hepatologist, Transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health at Stanford Health Care. In this video, she speaks about the Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer.   The goal of this study is to define the performance characteristics (sensitivity and specificity) of the Helio Liver Test in a study population of subjects with liver cancer at various stages (I to IV) and for control subjects who have been…

Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, Hepatologist, Transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health at Stanford Health Care. In this video, she speaks about the Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer.   The goal of this study is to define the performance characteristics (sensitivity and specificity) of the Helio Liver Test in a study population of subjects with liver cancer at various stages (I to IV) and for control subjects who have been…

Federico Aucejo, MD, is the Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic in the Department of General Surgery at Cleveland Clinic’s main campus.. In this video,  he speaks about the article Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases.   Question on Key Points What are the estimated overall and recurrence-free survival outcomes following living-donor liver transplantation (LDLT) in patients with liver-confined, unresectable colorectal cancer liver metastases (CRLM)?   Conclusions: At a median follow-up of 1.5 years, Kaplan-Meier estimates of recurrence-free and overall survival in this cohort analysis…

Federico Aucejo, MD, is the Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic in the Department of General Surgery at Cleveland Clinic’s main campus.. In this video,  he speaks about the article Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases.   Question on Key Points What are the estimated overall and recurrence-free survival outcomes following living-donor liver transplantation (LDLT) in patients with liver-confined, unresectable colorectal cancer liver metastases (CRLM)?   Conclusions: At a median follow-up of 1.5 years, Kaplan-Meier estimates of recurrence-free and overall survival in this cohort analysis…

Alberto Anel, Ph.D., Professor of Biochemistry, Department of Biochemistry and Molecular and Cellular Biology, Biochemistry and Molecular Biology Area, Science Faculty at the Universidad De Zaragoza. In this video, he speaks about the AACR 2022 Abstract – Mechanistic Insights On PT-112’s Effects On Prostate Cancer Cell Lines.   Overview:   To test PT-112 in a human prostate cancer cell panel for differential sensitivity, cell death mechanism, development of mitochondrial stress, and release of damage-associated molecular patterns (DAMPs).   Origins:   PT-112 is a new pyrophosphate-platinum compound that has shown therapeutic effectiveness in advanced solid cancers such as lung, thymoma, and…

Alberto Anel, Ph.D., Professor of Biochemistry, Department of Biochemistry and Molecular and Cellular Biology, Biochemistry and Molecular Biology Area, Science Faculty at the Universidad De Zaragoza. In this video, he speaks about the AACR 2022 Abstract – Mechanistic Insights On PT-112’s Effects On Prostate Cancer Cell Lines. Overview: To test PT-112 in a human prostate cancer cell panel for differential sensitivity, cell death mechanism, development of mitochondrial stress, and release of damage-associated molecular patterns (DAMPs). Origins:   PT-112 is a new pyrophosphate-platinum compound that has shown therapeutic effectiveness in advanced solid cancers such as lung, thymoma, and castration-resistant PC, as…

Umamaheswar Duvvuri, MD, Ph.D., FACS, Professor, Department of Otolaryngology at UPMC and the VA Pittsburg Health System. In this video, he speaks about the article Malaria drug could help treat chemotherapy-resistant head and neck cancers.   According to a new study, the malaria medicine hydroxychloroquine blocks mechanisms that develop resistance to the chemotherapeutic agent cisplatin in head and neck tumors and restores cisplatin’s tumor-killing properties in animal models.   The findings, reported today in the Proceedings of the National Academy of Sciences by scientists from the University of Pittsburgh and UPMC, clear the way for a clinical study combining cisplatin…

Umamaheswar Duvvuri, MD, Ph.D., FACS, Professor, Department of Otolaryngology at UPMC and the VA Pittsburg Health System. In this video, he speaks about the article Malaria drug could help treat chemotherapy-resistant head and neck cancers.   According to a new study, the malaria medicine hydroxychloroquine blocks mechanisms that develop resistance to the chemotherapeutic agent cisplatin in head and neck tumors and restores cisplatin’s tumor-killing properties in animal models.   The findings, reported today in the Proceedings of the National Academy of Sciences by scientists from the University of Pittsburgh and UPMC, clear the way for a clinical study combining cisplatin…

Sarbajit Mukherjee, MD, MS, Assistant Professor, Gastrointestinal Medical Oncologist at Roswell Park Cancer Institute. In this video, he speaks about the AACR 2022 Abstract – CT105 / 2 – Initial results of a phase II study evaluating a chemokine-modulatory (CKM) regimen in patients with colorectal cancer metastatic to the liver.   Abstract   Origins:   Liver metastases occur in 20-50 percent of colorectal cancer (CRC) patients, are resistant to immune checkpoint inhibitors (ICIs), and have a poor prognosis. Our preliminary findings demonstrated a synergistic effect of IFN and TLR3 ligands in selectively increasing the intratumoral production of CD8+ T cell…

Sarbajit Mukherjee, MD, MS, Assistant Professor, Gastrointestinal Medical Oncologist at Roswell Park Cancer Institute. In this video, he speaks about the AACR 2022 Abstract – CT105 / 2 – Initial results of a phase II study evaluating a chemokine-modulatory (CKM) regimen in patients with colorectal cancer metastatic to the liver.   Abstract   Origins:   Liver metastases occur in 20-50 percent of colorectal cancer (CRC) patients, are resistant to immune checkpoint inhibitors (ICIs), and have a poor prognosis. Our preliminary findings demonstrated a synergistic effect of IFN and TLR3 ligands in selectively increasing the intratumoral production of CD8+ T cell…

Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program, City of Hope. In this video, she speaks about the AACR 2022 Abstract – 5196 – CD47 Blockade potentiates immunotherapy of durvalumab against cutaneous T cell lymphoma.   View Immune checkpoint (IC) inhibition for PD1 and PD-Ligand 1 (PD-L1) has shown promising and long-term therapeutic effects in cutaneous T-cell lymphoma (CTCL), but resistance and/or relapses are prevalent. While most research has focused on increasing adaptive immune functions in CTCL, we looked into the role of 1) the “don’t eat me signal” (CD47) and PD-L1 as a dual (innate and adaptive IC)-targeting strategy…

Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program, City of Hope. In this video, she speaks about the AACR 2022 Abstract – 5196 – CD47 Blockade potentiates immunotherapy of durvalumab against cutaneous T cell lymphoma.   View   Immune checkpoint (IC) inhibition for PD1 and PD-Ligand 1 (PD-L1) has shown promising and long-term therapeutic effects in cutaneous T-cell lymphoma (CTCL), but resistance and/or relapses are prevalent. While most research has focused on increasing adaptive immune functions in CTCL, we looked into the role of 1) the “don’t eat me signal” (CD47) and PD-L1 as a dual (innate and adaptive IC)-targeting…

Tyler Nielsen, MBioMed, Staff Scientist at Oncocyte Corporation. In this video, he speaks about the AACR 22 Abstract – 1272 / 19 – Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs).   Outline   Origins:   Patients with mUC have a terrible prognosis, with less than 10% surviving two years following diagnosis. Because the majority of mUC patients do not survive to a second line of therapy, optimizing first-line therapy is crucial, particularly with recently approved non-ICI therapies.…

Tyler Nielsen, MBioMed, Staff Scientist at Oncocyte Corporation. In this video, he speaks about the AACR 22 Abstract – 1272 / 19 – Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs).   Outline   Origins:   Patients with mUC have a terrible prognosis, with less than 10% surviving two years following diagnosis. Because the majority of mUC patients do not survive to a second line of therapy, optimizing first-line therapy is crucial, particularly with recently approved non-ICI therapies.…

Laura Alder, MD, Hematology-Oncology Fellow at Duke University Health System. In this video, she speaks about the AACR 2022 Abstract 5257 – Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). Outline   Origins:   LMD is a catastrophic clinical consequence of metastatic breast cancer, with a 4.4-month median survival for the HER2+ subtype. There are few effective LMD therapies. T-DXd shown excellent extracranial effectiveness in the DESTINY-Breast01/03 trials for metastatic HER2+ breast cancer, including stable brain metastases (BrM) subgroups. T-effectiveness DXd’s in HER2+ untreated BrM…

Laura Alder, MD, Hematology-Oncology Fellow at Duke University Health System. In this video, she speaks about the AACR 2022 Abstract 5257 – Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). Outline   Origins:   LMD is a catastrophic clinical consequence of metastatic breast cancer, with a 4.4-month median survival for the HER2+ subtype. There are few effective LMD therapies. T-DXd shown excellent extracranial effectiveness in the DESTINY-Breast01/03 trials for metastatic HER2+ breast cancer, including stable brain metastases (BrM) subgroups. T-effectiveness DXd’s in HER2+ untreated BrM…

Michael J. Donovan, MD, Ph.D., Research Professor of Pathology, Molecular, and Cell-Based Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – 4145 / 8 – Novel approach that combines an automated breast cancer grading platform with genomics to personalize risk assessment and management. Observation – Origins: The use of histology in determining breast cancer (BCA) clinical risk assignment, including stage, tumor size, and histologic grade, remains an important component of treatment selection and management. Recent studies have shown the value of combining these characteristics with genetic signals such as…

Michael J. Donovan, MD, Ph.D., Research Professor of Pathology, Molecular, and Cell-Based Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – 4145 / 8 – Novel approach that combines an automated breast cancer grading platform with genomics to personalize risk assessment and management. Observation – Origins: The use of histology in determining breast cancer (BCA) clinical risk assignment, including stage, tumor size, and histologic grade, remains an important component of treatment selection and management. Recent studies have shown the value of combining these characteristics with genetic signals such as…

Jia Xu, Ph.D., Instructor – Oncological Sciences at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – LB195 / 8 – AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B.   Observation – The PI3K/AKT/mTOR signaling network is one of the most often dysregulated pathways in cancer development, and the serine/threonine kinase AKT serves as a critical node in this route, regulating various cellular and physiological processes. Clinical trials have shown that AKT inhibitors that competitively bind the…

Jia Xu, Ph.D., Instructor – Oncological Sciences at Icahn School of Medicine at Mount Sinai. In this video, he speaks about the AACR 2022 Abstract – LB195 / 8 – AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B.   Observation – The PI3K/AKT/mTOR signaling network is one of the most often dysregulated pathways in cancer development, and the serine/threonine kinase AKT serves as a critical node in this route, regulating various cellular and physiological processes. Clinical trials have shown that AKT inhibitors that competitively bind the…

Russell Rockne, Ph.D., associate professor, Department of Computational and Quantitative Medicine, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 2732 / 3 – A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy.   Observation –   Origins: Immunotherapy with chimeric antigen receptor – T (CAR-T) cells and targeted radionuclide therapy (TRT) are two promising cancer therapies. These medicines frequently have limited efficacy in completely eradicating cancer cells, making the combination of these two medications an appealing cancer treatment strategy. Because of the difficulties associated in administering and scheduling…

Russell Rockne, Ph.D., associate professor, Department of Computational and Quantitative Medicine, City of Hope. In this video, he speaks about the AACR 2022 Abstract – 2732 / 3 – A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy.   Observation –   Origins: Immunotherapy with chimeric antigen receptor – T (CAR-T) cells and targeted radionuclide therapy (TRT) are two promising cancer therapies. These medicines frequently have limited efficacy in completely eradicating cancer cells, making the combination of these two medications an appealing cancer treatment strategy. Because of the difficulties associated in administering and scheduling…